Is Mounjaro Better Than Ozempic for Losing Weight?

Last reviewed: June 24, 2026

Last updated: June 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Both tirzepatide and semaglutide reduce appetite and blood sugar, but tirzepatide activates the GLP-1 receptor and the GIP receptor, whereas semaglutide only targets GLP-1. Clinical trials show tirzepatide produces greater average weight loss, though individual results depend on metabolism, genetics, and adherence.

How Tirzepatide and Semaglutide Work Differently

Semaglutide mimics glucagon-like peptide-1 (GLP-1), a natural hormone that signals fullness and slows stomach emptying. It reduces hunger, decreases cravings, and helps regulate blood sugar. Tirzepatide does all of this—and activates a second pathway through the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual-hormone approach is called GLP-1/GIP receptor agonism.

The GIP pathway regulates energy expenditure and fat processing independently of appetite suppression. This means tirzepatide can influence weight loss through multiple biological channels. Both medications are injected weekly, but their different mechanisms explain why some patients respond better to one than the other.

Clinical Trial Results: Weight Loss Comparison

In head-to-head trials, tirzepatide produced average weight loss of 20–22% of body weight over 68 weeks at the highest doses. Semaglutide achieved 15–17% weight loss in similar timeframes. These percentages represent averages; individual outcomes vary based on dosing, lifestyle, and genetic factors. Neither medication guarantees identical results across all users.

Tirzepatide's advantage appears strongest in people with insulin resistance or metabolic dysfunction. Semaglutide remains highly effective and may be sufficient for patients with less severe obesity or those who tolerate single-pathway activation better. The 'better' medication depends on your body's response, not the drug itself.

Cost and Access Without Insurance

PlexusDx offers compounded tirzepatide injection starting at $249 per month, with no insurance required and no membership fees. Compounded semaglutide injection begins at $149 per month. Both are HSA/FSA eligible, making them accessible to patients who self-pay or use health savings accounts. PlexusDx sources all medications from licensed 503A compounding pharmacies to ensure quality and consistency.

Your dose may need to go up as your body adapts, but your monthly price won't. This flat-rate pricing model removes the financial barrier that often prevents people from accessing weight-loss therapy. Patients can request either medication based on clinical preference and budget.

Genetic Testing Reveals Your Best Medication Match

PlexusDx Precision Peptide Genetic Test analyzes variants in the GLP1R, GIPR, FTO, and MC4R genes—key regulators of appetite, energy use, and weight storage. Genetic differences at these loci predict how your body will respond to GLP-1 activation, GIP activation, and weight-loss therapy in general. Testing costs $99 after your first month of treatment and maps 14 biological pathways across 49 peptides.

If your genetic profile shows strong GLP1R activation capacity, you may achieve excellent results on semaglutide alone. If your GIPR variant predicts robust GIP-pathway responsiveness, tirzepatide may unlock faster fat loss. Genetic insight removes guesswork and helps PlexusDx clinicians tailor medication selection to your unique metabolism.

Side Effects and Tolerability

Both tirzepatide and semaglutide commonly cause nausea, constipation, and vomiting, especially during dose escalation. These effects typically fade within 2–4 weeks as your body adapts. Tirzepatide may produce slightly more gastrointestinal symptoms in early weeks because it acts on two receptor pathways; some patients tolerate semaglutide more comfortably at the outset.

Serious side effects (pancreatitis, thyroid issues, severe dehydration) are rare and reported in both drugs at similar frequencies. Gradual dose increases—called titration—reduce nausea risk. If side effects become intolerable on one medication, switching to the other is clinically reasonable and supported by shared medical decision-making.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Which medication will make me lose more weight: tirzepatide or semaglutide?

Clinical trials show tirzepatide produces 20–22% average weight loss versus 15–17% for semaglutide, but individual outcomes vary. Your genetics, adherence, diet, and activity level matter more than the drug name. PlexusDx genetic testing can reveal which pathway—GLP-1 or GIP—your body responds to most effectively.

Is tirzepatide the same as Mounjaro?

Tirzepatide is the active ingredient in Mounjaro (brand-name insulin pen) and Zepbound (weight-loss formulation). PlexusDx compounded tirzepatide injection contains the same active compound but costs less and requires no insurance. All PlexusDx medications come from licensed 503A compounding pharmacies.

Can I switch from semaglutide to tirzepatide if I'm not seeing results?

Yes, switching is safe and straightforward. Some patients respond better to dual GLP-1/GIP activation than single GLP-1 activation. Discuss your weight-loss timeline and tolerability with your PlexusDx clinician; they can adjust your medication and optimize your dose schedule.

Why does PlexusDx charge a flat price instead of charging by dose?

Flat-rate pricing removes financial barriers to dose escalation. Your dose may need to go up to reach your weight-loss goals, but your monthly price won't increase. This model ensures affordability as your body adapts and your clinician adjusts therapy.

How does the Precision Peptide Genetic Test help me choose between tirzepatide and semaglutide?

The test analyzes GLP1R, GIPR, FTO, and MC4R variants to predict your metabolic response. Strong GLP1R activation may favor semaglutide; strong GIPR activation may favor tirzepatide. Genetic insights guide PlexusDx clinicians to personalize your medication for maximum efficacy and tolerability.

Do I need insurance to get tirzepatide from PlexusDx?

No. PlexusDx serves all 50 states with no insurance requirement and no membership fee. Tirzepatide injection starts at $249 per month and is HSA/FSA eligible, making it accessible to self-pay patients and those with health savings accounts.

Related Reading

• Ozempic For Losing Weight
• Mounjaro For Losing Weight
• Glp 1 For Losing Weight
• Zepbound For Losing Weight

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.